

Biological reactive intermediates that mediate dacarbazine cytotoxicity

Jalal Pourahmad · Marzieh Amirmostofian ·
Farzad Kobarfard · Jafar Shahraki

Received: 10 December 2008 / Accepted: 8 April 2009 / Published online: 28 April 2009
© Springer-Verlag 2009

Abstract

Purpose In the following, the cellular and molecular mechanism of cytotoxicity induced by prodrug dacarbazine toward the isolated rat hepatocytes was studied.

Method Accelerated cytotoxicity screening technique (ACMS) was used to perform this study.

Result Addition of dacarbazine to isolated rat hepatocytes resulted in reactive oxygen species (ROS) formation, and lysosomal membrane leakiness before hepatocyte lysis occurred. Hepatocyte ROS generation was inhibited by desferoxamine (a ferric chelator). Cytotoxicity was prevented by antioxidants or ROS scavengers (mannitol or dimethylsulfoxide), cytochrome P450 inhibitors (phenylimidazole, diphenyliodonium chloride, 4-methylpyrazole, and benzylimidazole). In addition to lysosomal damage, dacarbazine caused hepatocyte protease activation and cell proteolysis.

Conclusion Dacarbazine cytotoxicity is associated with ROS (H_2O_2 , $O_2^{\bullet-}$) generation. It is suggested that H_2O_2 could cross the lysosomal membrane, react with lysosomal Fe^{2+} to form hydroxyl radical (Haber-Weiss reaction) which is the major cause of lysosomal membrane leakiness, proteases, and other digestive enzymes' release and finally the cell death.

Keywords Dacarbazine · Oxidative stress · CYP450 · Biological reactive intermediate · Cytotoxicity · Lysosome

Abbreviations

DTIC	5-(3, 3-Dimethyl-1-triazeno)-imidazole-4-carboxamide
MTIC	5-(3-Monomethyl-1-triazeno)-imidazole-4-carboxamide
AIC	Aminoimidazole carboxamide
ROS	Reactive oxygen species
SD	Standard deviation
ANOVA	Analysis of variance
DMSO	Dimethylsulfoxide
DCF	Dichlorofluorescein
HEPES	(2-Hydroxyethyl)-1-piperazine-ethansulfonic acid
h	Hour
BHA	Butylated hydroxyanisole
BHT	Butylated hydroxy toluene

Introduction

5-(3,3-Dimethyl-1-triazeno)-imidazole-4-carboxamide (Dacarbazine, DTIC) is a synthetic chemical antitumor agent, which is used to treat malignant melanoma and Hodgkin's disease [1–6]. Although the exact mechanism of Dacarbazine has not yet been completely known, three hypotheses have so far been offered: (a) inhibition of DNA synthesis by acting as a purine analogue, (b) action as alkylating agent, (c) interaction with SH groups [7–9]. By detection of aminoimidazole carboxamide, AIC, (C14) in urine and separation of N-7 and O-6 from DNA strands, its primary mode of action appears to be alkylation of nucleic acid [9–13]. However, DTIC is a prodrug, which becomes activated by N-demethylation in liver microsomes [4, 14, 15] and 5-(3-monomethyl-1-triazeno)-imidazole-4-carboxamide (MTIC)

J. Pourahmad (✉) · M. Amirmostofian · F. Kobarfard ·
J. Shahraki

Faculty of Pharmacy, Shaheed Beheshti University of Medical
Sciences, Tehran, P.O. Box 14155-6153, Iran
e-mail: j.pourahmadjaktaji@utoronto.ca

is formed. The liver's microsomal enzymes (CYP1A1, CYP1A2, and CYP2E1) could hydroxylate and N-demethylate the dacarbazine [4, 14, 15]. However, all enzymes which are effective on DTIC metabolism have not yet been completely investigated, but with specific antibodies (CYP1A abs) and specific microsomal enzyme inhibitors (phenobarbital and leptoflavon), the relationship between N-demethylase and CYP1A (CYP1A1 and CYP1A2) isoenzymes were found [4]. Then, MTIC spontaneously decomposes to AIC and methyldiazonium, which is subsequently changed to methyl carbanion which has a capability to methylate the DNA strand on N-7 of Guanine [10–12, 16–18; Fig. 1).

In the following, the cellular and molecular mechanism of cytotoxicity induced by dacarbazine toward the isolated rat hepatocytes was studied. Based on previous literature and also our pilot study, we postulated that the cytotoxicity of DTIC may involve metabolic activation leading to biological reactive intermediates formation which can activate cytosolic oxygen and generate reactive oxygen species.

Materials and methods

Chemicals

5-(3,3-Dimethyl-1-triazeno)-imidazole-4-carboxamide (Dacarbazine, DTIC) was obtained from drug store. Collagenase (from *Clostridium histolyticum*), bovine serum albumin

(BSA), Hepes, trypan blue, d-mannitol, dimethyl sulfoxide, butylated hydroxy toluene (BHT), butylated hydroxyanisole (BHA), chloroquine diphosphate, methylamine HCl, 3-methyl adenine, monensin sodium, leupeptin, pepstatin, ethylene glycol-bis (p-aminoethyl ether) *N,N,N',N'*-tetra acetic acid (EGTA), Gentamycin, Aurothioglucose, and heparin were obtained from Sigma (Taufkirchen, Germany). Acridine orange and dichlorofluorescein diacetate were purchased from Molecular Probes (Eugene, Ore, USA). Desferoxamine was a gift from Ciba-Geigy Canada Ltd. (Toronto, ON, Canada). All chemicals were of the highest commercial grade available.


Animals

Male Sprague-Dawley rats (280–300 g), fed on a standard chow diet and given water ad libitum, were used in all experiments.

Isolation and incubation of hepatocytes

Hepatocytes were obtained by collagenase perfusion of the liver as described by Pourahmad and O'Brien in 2000 [19]. Approximately, 85–90% of the hepatocytes excluded trypan blue. Cells were suspended at a density of 10^6 cells/ml in round bottomed flasks rotating in a water bath maintained at 37°C in Krebs-Henseleit buffer (pH 7.4), supplemented with 12.5 mM Hepes under an atmosphere of 10% O₂, 85% N₂, and 5% CO₂. Each flask contained 10 ml of hepatocyte suspension. Hepatocytes were preincubated

Fig. 1 DTIC becomes activated by the liver's microsomal enzymes (CYP450) and formed MTIC. Then MTIC spontaneously decomposes to AIC and methyldiazonium. The latter has a capability to methylate the DNA strand on N-7 of Guanine



for 30 min prior to addition of chemicals. Stock solutions of all chemicals ($\times 100$ concentrated for the water solutions or $\times 1,000$ concentrated for the methanolic solutions) were prepared fresh prior to use. To avoid either non toxic or very toxic conditions in this study, we used $EC_{50_{2h}}$ concentration for DTIC in the isolated hepatocytes (56 μM). The EC_{50} of a chemical in ACMS technique (ACMS: Accelerated Cytotoxicity Mechanism Screening) (with the total 3 h incubation period), is defined as the concentration which decreases the hepatocyte viability down to 50% following the 2 h of incubation. In order to determine this value for the investigated compound, dose–response curves were plotted and then EC_{50} was determined based on a regression plot of three different concentrations [20].

The $EC_{50_{2h}}$ of DTIC in hepatocyte cytotoxicity assessment technique (with the total 3 h incubation period) is defined as the concentration, which decreases the hepatocyte viability down to 50% following the 2 h of incubation. In order to determine this value for the investigated compound, dose–response curves were plotted, and then $EC_{50_{2h}}$ was determined based on a regression plot of four different concentrations (10, 20, 50, and 100 μM) (data are shown below).

Cytotoxicity of DTIC at different concentration following the 2 h of incubation in rat hepatocyte

Addition	Cytotoxicity (2 h)			
	10 μM	20 μM	50 μM	100 μM
Dacarbazine	35 \pm 2	40 \pm 2	48 \pm 2	64 \pm 3

Hepatocytes (10^6 cells/ml) were incubated in Krebs-Henseleit buffer pH 7.4 at 37°C

Values are expressed as means of three separate experiments (SD)

For the chemicals which dissolved in water, we added 100 μl sample of its concentrated stock solution ($\times 100$ concentrated) to one rotating flask containing 10 ml hepatocyte suspension. For the chemicals which dissolved in methanol, we prepared methanolic stock solutions ($\times 1,000$ concentrated), and to achieve the required concentration in the hepatocytes, we added 10 μl samples of the stock solution to the 10 ml cell suspension. Ten microliters of methanol did not affect the hepatocyte viability after 4 h incubation (data not shown). All the inhibitors were preincubated 30 min prior to DTIC addition.

Cell viability

The viability of isolated hepatocytes was assessed from the intactness of the plasma membrane as determined by the

trypan blue [0.2% (w/v)] exclusion test [19]. Aliquots of the hepatocyte incubate were taken at different time points during the 3 h incubation period. At least 80–90% of the control cells were still viable after 3 h.

Determination of ROS

To determine the rate of hepatocyte “ROS” generation, dichlorofluorescein diacetate was added to the hepatocyte incubate as it penetrates hepatocytes and becomes hydrolyzed to non-fluorescent dichlorofluorescein. The latter then reacts with “ROS” to form the highly fluorescent dichlorofluorescein which effluxes the cell. Hepatocytes (1×10^6 cells/ml) were suspended in 10 ml modified Hank’s balanced salt solution (HBS), adjusted to pH 7.4 with 10 mM Hepes (HBSH), and were incubated with DTIC at 37°C for 30 min. After centrifugation (50g, 1 min), the cells were resuspended in HBS adjusted to pH 7.4 with 50 mM Tris–HCl and loaded with dichlorofluorescein by incubating with 1.6 μM dichlorofluorescein diacetate for 2 min at 37°C. The fluorescence intensity of the “ROS” product was measured using a Shimadzu RF5000U fluorescence spectrophotometer. Excitation and emission wavelengths were 500 nm and 520 nm, respectively. The results were expressed as fluorescent intensity per 10^6 cells [21].

Lysosomal membrane stability assay

Hepatocyte lysosomal membrane stability was determined from the redistribution of the fluorescent dye, acridine orange [22]. Aliquots of the cell suspension (0.5 ml) that were previously stained with acridine orange 5 μM were separated from the incubation medium by centrifugation (50g, 1 min). The cell pellet was then resuspended in 2 ml of fresh incubation medium. This washing process was carried out twice to remove the fluorescent dye from the media. Acridine orange redistribution in the cell suspension was then measured fluorimetrically using a Shimadzu RF5000U fluorescence spectrophotometer set at 470 nm excitation and 540 nm emission wavelengths.

Lipid peroxidation assay

Hepatocyte lipid peroxidation was determined by measuring the amount of thiobarbituric acid-reactive substances (TBARS) formed during the decomposition of lipid hydroperoxides by following the absorbance at 532 nm in a Beckman DU®-7 spectrophotometer after treating 1.0 ml aliquots of hepatocyte suspension (10^6 cells/ml) with trichloroacetic acid [70% (w/v)] and oiling the suspension with thiobarbituric acid [0.8% (w/v)] for 20 min [19].

Statistical analysis

Levene's test was used for homogeneity of variances. Data were analysed using one-way analysis of variance (ANOVA) followed by Tukey Post-test. Results represent the mean \pm standard deviation of the mean (SD) of triplicate samples. The minimal level of significance chosen was $P \leq 0.05$.

Results

When hepatocytes were incubated with 56 μ M DTIC, the formation of "ROS" was increased very rapidly (peak in about 30 min, curve not shown) in a concentration dependent fashion (Table 2). The antioxidants: α -tocopherol succinate, BHT, BHA, and "ROS" scavengers [24],

Table 1 Preventing DTIC cytotoxicity by antioxidants, "ROS" scavengers, lysosomal protease inhibitors, and lysosomotropic agents

Addition	%Cytotoxicity		
	1 h	2 h	3 h
None	15 \pm 2	17 \pm 2	20 \pm 2
Dacarbazine (56 μ M)	38 \pm 3 ⁽¹⁾	55 \pm 3 ⁽¹⁾	76 \pm 4 ⁽¹⁾
+BHA (50 μ M)	26 \pm 3 ⁽²⁾	32 \pm 3 ⁽²⁾	43 \pm 4 ⁽²⁾
+BHT(50 μ M)	27 \pm 2 ⁽²⁾	33 \pm 2 ⁽²⁾	42 \pm 3 ⁽²⁾
+Dimethyl sulfoxide (150 μ M)	26 \pm 2 ⁽²⁾	30 \pm 3 ⁽²⁾	44 \pm 3 ⁽²⁾
+Mannitol (50 mM)	28 \pm 3 ⁽²⁾	33 \pm 3 ⁽²⁾	48 \pm 3 ⁽²⁾
+Desferoxamine (200 μ M)	24 \pm 3 ⁽²⁾	28 \pm 2 ⁽²⁾	36 \pm 2 ⁽²⁾
+ α -Tocopherol succinate (100 μ M)	26 \pm 2 ⁽²⁾	33 \pm 3 ⁽²⁾	41 \pm 4 ⁽²⁾
+4-Methylpyrazole (500 μ M)	35 \pm 3 ⁽²⁾	42 \pm 3 ⁽²⁾	50 \pm 2 ⁽²⁾
+Benzylimidazole (100 μ M)	38 \pm 2 ⁽²⁾	44 \pm 5 ⁽²⁾	56 \pm 2 ⁽²⁾
+Phenylimidazole (300 μ M)	36 \pm 3 ⁽²⁾	41 \pm 4 ⁽²⁾	53 \pm 3 ⁽²⁾
+Diphenyliodoniumchloride (50 μ M)	37 \pm 4 ⁽²⁾	42 \pm 4 ⁽²⁾	48 \pm 5 ⁽²⁾
+Leupeptine (50 μ M)	22 \pm 2 ⁽²⁾	28 \pm 3 ⁽²⁾	42 \pm 4 ⁽²⁾
+Pepstatine (50 μ M)	20 \pm 2 ⁽²⁾	26 \pm 3 ⁽²⁾	40 \pm 4 ⁽²⁾
+Monensin (10 μ M)	27 \pm 2 ⁽²⁾	39 \pm 3 ⁽²⁾	51 \pm 2 ⁽²⁾
+Methylamine (30 mM)	18 \pm 2 ⁽²⁾	25 \pm 2 ⁽²⁾	36 \pm 4 ⁽²⁾
+Chloroquine (100 μ M)	17 \pm 2 ⁽²⁾	24 \pm 2 ⁽²⁾	40 \pm 3 ⁽²⁾
+3-Methyladenine (5 mM)	18 \pm 1 ⁽²⁾	25 \pm 2 ⁽²⁾	36 \pm 4 ⁽²⁾
+Gentamycin (1.5 mM)	56 \pm 3 ⁽²⁾	72 \pm 3 ⁽²⁾	93 \pm 4 ⁽²⁾
+Aurothioglucose (1.5 mM)	57 \pm 2 ⁽²⁾	73 \pm 2 ⁽²⁾	92 \pm 3 ⁽²⁾

Hepatocytes (10^6 cells/ml) were incubated in Krebs-Henseleit buffer pH 7.4 at 37°C for 3.0 hrs

Following the addition of DTIC. Cytotoxicity was determined as the percentage of cells that take up trypan blue [17]

Values are expressed as means of three separate experiments (SD)

⁽¹⁾ Significant difference in comparison with control hepatocytes ($P < 0.05$)

⁽²⁾ Significant difference in comparison with DTIC treated hepatocytes ($P < 0.05$)

mannitol and dimethylsulfoxide (DMSO) protected the hepatocytes against DTIC-induced cytotoxicity, as well as, "ROS" generation. None of these antioxidants alone affected hepatocytes viability at the concentrations used (data not shown).

However, the CYP2E1 inhibitors phenylimidazole, 4-methylpyrazole, benzylimidazole and NADPH P450 reductase inhibitor diphenyliodonium chloride (DPI) [24–27] showed significant effect on DTIC-induced cell lysis and "ROS" formation and protected the hepatocytes against dacarbazine. Lysosomotropic agents including chloroquine [28], methylamine [29], monensin (a Na⁺ ionophore that inhibits hepatocyte endosomal acidification) [30], and 3-methyladenine (an inhibitor of hepatocyte autophagy) [31] also protected the hepatocytes against DTIC-induced cell lysis and "ROS" formation (Tables 1, 2). All of these agents did not show any toxic effect on hepatocytes at concentrations used (data not shown).

When hepatocyte lysosomes were preloaded with acridine orange, a release of acridine orange into the cytosolic fraction ensued within 30 min after treating the loaded

Table 2 Preventing DTIC "ROS" formation by antioxidants, "ROS" scavengers, endocytosis inhibitors, and lysosomotropic agents

Addition	"ROS"		
	2 min	15 min	30 min
None	66 \pm 2	73 \pm 4	79 \pm 4
Dacarbazine (56 μ M)	150 \pm 7 ⁽¹⁾	194 \pm 8 ⁽¹⁾	230 \pm 4 ⁽¹⁾
+BHA (50 μ M)	81 \pm 4 ⁽²⁾	98 \pm 3 ⁽²⁾	121 \pm 4 ⁽²⁾
+BHT(50 μ M)	77 \pm 3 ⁽²⁾	84 \pm 3 ⁽²⁾	118 \pm 4 ⁽²⁾
+Dimethyl sulfoxide (150 μ M)	81 \pm 3 ⁽²⁾	93 \pm 2 ⁽²⁾	121 \pm 2 ⁽²⁾
+Mannitol (50 mM)	85 \pm 4 ⁽²⁾	103 \pm 4 ⁽²⁾	136 \pm 3 ⁽²⁾
+Desferoxamine (200 μ M)	108 \pm 5 ⁽²⁾	111 \pm 4 ⁽²⁾	121 \pm 3 ⁽²⁾
+ α -Tocopherol succinate (100 μ M)	77 \pm 2 ⁽²⁾	88 \pm 4 ⁽²⁾	11 \pm 3 ⁽²⁾
+4-Methylpyrazole (500 μ M)	116 \pm 5 ⁽²⁾	117 \pm 3 ⁽²⁾	167 \pm 4 ⁽²⁾
+Benzylimidazole (100 μ M)	110 \pm 3 ⁽²⁾	119 \pm 4 ⁽²⁾	165 \pm 3 ⁽²⁾
+Phenylimidazole (300 μ M)	108 \pm 4 ⁽²⁾	115 \pm 4 ⁽²⁾	161 \pm 3 ⁽²⁾
+Diphenyliodoniumchloride (50 μ M)	111 \pm 5 ⁽²⁾	122 \pm 5 ⁽²⁾	166 \pm 3 ⁽²⁾
+Monensin (10 μ M)	125 \pm 5 ⁽²⁾	131 \pm 7 ⁽²⁾	161 \pm 2 ⁽²⁾
+Methylamine (30 mM)	107 \pm 4 ⁽²⁾	111 \pm 6 ⁽²⁾	117 \pm 3 ⁽²⁾
+Chloroquine (100 μ M)	111 \pm 5 ⁽²⁾	115 \pm 6 ⁽²⁾	128 \pm 2 ⁽²⁾
+3-Methyladenine (5 mM)	118 \pm 5 ⁽²⁾	125 \pm 4 ⁽²⁾	132 \pm 4 ⁽²⁾

Hepatocytes (10^6 cells/ml) were incubated in Krebs-Henseleit buffer pH 7.4 at 37°C for 30 min

DCF formation was expressed as fluorescent intensity units [18]

Values are expressed as means of three separate experiments (SD)

⁽¹⁾ Significant difference in comparison with control hepatocytes ($P < 0.05$)

⁽²⁾ Significant difference in comparison with DTIC treated hepatocytes ($P < 0.05$)

Table 3 Preventing DTIC-induced hepatocyte lysosomal membrane damage by inhibitors of oxidative stress, “ROS” scavengers and lysosomotropic agents

Addition	Acridine orange redistribution		
	2 min	15 min	30 min
None	2 ± 1	4 ± 2	4 ± 3
Dacarbazine (56 µM)	183 ± 5 ⁽¹⁾	237 ± 5 ⁽¹⁾	250 ± 4 ⁽¹⁾
+BHA(50 µM)	10 ± 1 ⁽²⁾	14 ± 2 ⁽²⁾	23 ± 2 ⁽²⁾
+BHT(50 µM)	14 ± 1 ⁽²⁾	19 ± 2 ⁽²⁾	25 ± 3 ⁽²⁾
+Mannitol (50 mM)	8 ± 2 ⁽²⁾	11 ± 1 ⁽²⁾	13 ± 1 ⁽²⁾
+Desferoxamine (200 µM)	8 ± 2 ⁽²⁾	10 ± 2 ⁽²⁾	11 ± 1 ⁽²⁾
+4-Methylpyrazole (500 µM)	18 ± 2 ⁽²⁾	24 ± 3 ⁽²⁾	31 ± 2 ⁽²⁾
+Benzylimidazole (100 µM)	17 ± 2 ⁽²⁾	23 ± 3 ⁽²⁾	36 ± 2 ⁽²⁾
+Phenylimidazole (300 µM)	16 ± 2 ⁽²⁾	22 ± 1 ⁽²⁾	30 ± 3 ⁽²⁾
+Diphenyliodoniumchloride (50 µM)	18 ± 3 ⁽²⁾	26 ± 3 ⁽²⁾	33 ± 3 ⁽²⁾
+Monensin (10 µM)	21 ± 2 ⁽²⁾	25 ± 3 ⁽²⁾	32 ± 3 ⁽²⁾
+Methylamine (30 mM)	8 ± 2 ⁽²⁾	11 ± 1 ⁽²⁾	14 ± 1 ⁽²⁾
+Chloroquine (100 µM)	12 ± 1 ⁽²⁾	15 ± 2 ⁽²⁾	20 ± 2 ⁽²⁾
+3-Methyladenine (5 mM)	13 ± 1 ⁽²⁾	18 ± 2 ⁽²⁾	26 ± 3 ⁽²⁾

Hepatocytes (10⁶ cells/ml) were incubated in Krebs-Henseleit buffer pH 7.4 at 37°C

Lysosomal membrane damage was determined as intensity unit of diffuse cytosolic green fluorescence induced by acridine orange following the release from lysosome [19]

Values are expressed as means of three separate experiments (SD)

⁽¹⁾ Significant difference in comparison with control hepatocytes ($P < 0.05$)

⁽²⁾ Significant difference in comparison with DTIC treated hepatocytes ($P < 0.05$)

hepatocytes with 56 µM of DTIC (Table 3). The DTIC-induced acridine orange release, which is a marker of lysosomal membrane damage, was prevented by ROS scavengers including dimethylsulfoxide, mannitol, BHT, BHA, or desferoxamine (Table 3). Phenylimidazole, 4-methylpyrazole, benzylimidazole, and NADPH P450 reductase inhibitor diphenyliodonium chloride (DPI) also inhibited dacarbazine acridine orange release (Table 3). The dacarbazine-induced acridine orange redistribution was prevented by 3-methyladenine, chloroquine, methylamine, monensin (Table 3), and dacarbazine-induced hepatocytes cytotoxicity was prevented by the lysosomal protease inhibitors [32–34; Table 1). None of these agents alone at the concentrations used show any significant effect on acridine orange release in acridine orange-loaded hepatocytes (data not shown). Hepatocyte proteolysis as determined by the release of the amino acid tyrosine into the extracellular medium over 120 min was next measured. Hepatocyte proteolysis was markedly increased, when hepatocytes were incubated with DTIC and was completely prevented by the lysosomal protease inhibitors leupeptin

Table 4 Preventing DTIC-Induced hepatocyte proteolysis with inhibitors of oxidative stress lysosomotropic agents and lysosomal protease inhibitors

Addition	Hepatocyte tyrosine release (µM)		
	30 min	60 min	120 min
None	10 ± 1	12 ± 1	21 ± 2
Dacarbazine (56 µM)	57 ± 3 ⁽¹⁾	89 ± 2 ⁽¹⁾	120 ± 3 ⁽¹⁾
+Dimethyl sulfoxide (150 µM)	14 ± 2 ⁽²⁾	21 ± 3 ⁽²⁾	32 ± 2 ⁽²⁾
+Mannitol (50 mM)	15 ± 3 ⁽²⁾	27 ± 2 ⁽²⁾	39 ± 2 ⁽²⁾
+BHT(50 µM)	14 ± 2 ⁽²⁾	24 ± 2 ⁽²⁾	33 ± 3 ⁽²⁾
+BHA(50 µM)	12 ± 3 ⁽²⁾	20 ± 5 ⁽²⁾	36 ± 2 ⁽²⁾
+Desferoxamine (200 µM)	15 ± 3 ⁽²⁾	31 ± 2 ⁽²⁾	46 ± 3 ⁽²⁾
+Monensin (10 µM)	16 ± 2 ⁽²⁾	27 ± 3 ⁽²⁾	38 ± 4 ⁽²⁾
+Methylamine (30 mM)	13 ± 3 ⁽²⁾	31 ± 4 ⁽²⁾	45 ± 2 ⁽²⁾
+Chloroquine (100 µM)	15 ± 4 ⁽²⁾	29 ± 3 ⁽²⁾	37 ± 4 ⁽²⁾
+3-Methyladenine (5 mM)	18 ± 5 ⁽²⁾	33 ± 2 ⁽²⁾	43 ± 4 ⁽²⁾
+Leupeptine (50 µM)	14 ± 3 ⁽²⁾	30 ± 3 ⁽²⁾	41 ± 2 ⁽²⁾
+Pepstatine (50 µM)	15 ± 4 ⁽²⁾	28 ± 4 ⁽²⁾	45 ± 3 ⁽²⁾
+Gentamycin (1.5 mM)	103 ± 2 ⁽²⁾	202 ± 4 ⁽²⁾	308 ± 4 ⁽²⁾
+Aurothioglucose (1.5 mM)	113 ± 3 ⁽²⁾	94 ± 5 ⁽²⁾	332 ± 3 ⁽²⁾

Hepatocytes (10⁶ cells/ml) were incubated in Krebs-Henseleit buffer pH 7.4 at 37°C

Lysosomal induced proteolysis was determined by measuring the cellular release of tyrosine into the media [23]

Values are expressed as means of three separate experiments (SD)

⁽¹⁾ Significant difference in comparison with control hepatocytes ($P < 0.05$)


⁽²⁾ Significant difference in comparison with DTIC treated hepatocytes ($P < 0.05$)

and pepstatin or the ROS scavengers dimethylsulfoxide, mannitol, BHT, BHA and desferoxamine (Table 4). However, the lysosomal protease inhibitors (leupeptin and pepstatin) did not affect DTIC-induced hepatocyte acridine orange release (data not shown). The DTIC-induced proteolysis was also inhibited by 3-methyladenine, chloroquine, and methylamine. On the other hand, gentamycin and aurothioglucose which can release lysosomal proteases [35, 36] significantly increased DTIC-induced cell lysis and hepatocyte proteolysis (Tables 1, 4). None of these agents alone show any toxic effect on hepatocytes at concentrations used (data not shown).

Discussion

We have shown that dacarbazine was cytotoxic toward isolated hepatocytes, and the antioxidants and “ROS” scavengers prevented DTIC-induced “ROS” formation and cytotoxicity suggesting that ROS formation contributes to DTIC-induced cell lysis (Tables 1, 2).

Fig. 2 The biological reactive intermediate that is shown as a compound II is formed following demethylation of DTIC by CYP450 isoenzymes which produced MTIC. Then, MTIC is spontaneously changed to its other isomers (compound I and II). When compound II reacts to cytosolic oxygen, after some electron shifts (shown in Fig 2), three substrates are formed which one of them is a reactive oxygen species ($\text{CH}_3\text{-O-O}^\bullet$) that is highly reactive



It was already suggested that methylation of the nucleic acid is the only mechanism involved in DTIC cytotoxicity [9–13]. However, our results showed sharp increase in “ROS” formation following the treatment of hepatocytes with DTIC (Table 2).

Preincubation of hepatocytes with the CYP2E1 inhibitors phenylimidazole, 4-methylpyrazole, benzylimidazole, and NADPH P450 reductase inhibitor diphenyliodonium chloride (DPI) prevented both dacarbazine-induced cytotoxicity and ROS formation which suggested that reduced CYP2E1 or P450 reductase reductively activate dacarbazine.

Dacarbazine cytotoxicity, as well as, hepatocyte ROS formation were prevented by the lysosomotropic agents (lysosomal inactivators), chloroquine [28], methylamine [29], monensin (a Na^+ ionophore that inhibits hepatocyte

endocytosis and endosomal acidification) [30], or 3-methyladenine (an inhibitor of hepatocyte autophagy) [31]. The hepatocyte lysosomal protease inhibitors leupeptin or pepstatin [32–34] also prevented dacarbazine-induced cytotoxicity. The ferric chelator desferoxamine also prevented hepatocyte cytotoxicity induced by DTIC.

In addition, dacarbazine induced lysosomal membrane leakiness, since acridine orange was readily redistributed from lysosome to cytosol following incubation of DTIC in the acridine orange-loaded hepatocytes. Hepatocyte lysosomal leakiness occurred within 30 min following addition of DTIC, before toxicity ensued (Table 3). Lysosomal leakiness was prevented by the hepatocyte lysosomotropic agents (lysosomal inactivators); methylamine, chloroquine, monensin, and 3-methyladenine (Table 3).




Fig. 3 $\text{CH}_3\text{-O-O}\cdot$ will react with cellular water and generate H_2O_2 and methyl radical ($\text{CH}_3\cdot$) which are very active radical species and probably is responsible for DNA methylation. The lipophilic H_2O_2 will easily cross the lysosomal lipid membrane and interact with lysosomal $\text{Fe}^{2+}/\text{Fe}^{3+}$ (Haber-Weiss reaction) which leads to hydroxyl radical ($\text{OH}\cdot$) formation, causing lysosomal membrane oxidative damage which is the reason for lysosomal digestive enzymes release

In general, our results suggested that dacarbazine-induced hepatocyte toxicity involves reductive activation by reduced cytochrome P450 or NADPH-P450 reductase to form a biological reactive intermediate which can activate cytosolic oxygen and induce ROS formation. On the other hand, the biological reactive intermediate, which is shown as compound II (Fig 2), is formed following demethylation of DTIC by CYP450 isoenzymes which produced MTIC. Then, MTIC is spontaneously changed to its other isomers (compound I and II) (Fig 2). When compound II reacts to cytosolic oxygen, after some electron shifts (Fig 2), three substances are formed, one of which is the free radical $\text{CH}_3\text{-O-O}\cdot$, a highly reactive species. It will then react with cellular water to generate H_2O_2 and the methyl radical ($\text{CH}_3\cdot$). $\text{CH}_3\cdot$ is probably responsible for DNA methylation (Fig. 3).

The lipophilic H_2O_2 will easily cross the lysosomal lipid membrane and interact with lysosomal $\text{Fe}^{2+}/\text{Fe}^{3+}$ (Haber-Weiss reaction) which leads to hydroxyl radical ($\text{OH}\cdot$)

formation, causing lysosomal membrane oxidative damage and leakiness which is the reason for lysosomal digestive enzymes release into cytosol. Previously it was shown that gentamycin and aurothioglucose depleted lysosomal proteases [35, 36]. Our findings that nontoxic concentrations of gentamicin or aurothioglucose markedly increased DTIC-induced cytotoxicity and hepatocyte proteolysis (Tables 1, 4) further suggest that the lysosomal release of proteases contributes to the DTIC-induced cytotoxic mechanism.

These results also suggest that DTIC-induced hepatocyte toxicity involves oxidative stress through the formation of several reactive oxygen species. So it is concluded that monomethyl free radicals ($\text{CH}_3\text{-O-O}\cdot$, $\text{CH}_3\cdot$) and hydrogen peroxide are the result of the reductive activation of DTIC by liver CYP450 isoenzyme (CYP2E1). The hydrogen peroxide generated results in the formation of the highly reactive hydroxyl radical ($\text{OH}\cdot$). These reactive species could attack many cellular substrates including cell membranes, suborganel membranes, and DNA strands (Fig 3).

References

- Beretta G, Bonadonna G, Bajetta E, Tancini G, De Lena M, Azzarelli A, Veronesi U (1976) Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease. *Cancer Treat Rep* 60(2):205–211
- Johnson RO, Metter G, Wilson W, Hill G, Kremenz E (1976) Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. *Cancer Treat Rep* 60(2):183–187
- Costanzi JJ (1976) DTIC (NSC-45388) studies in the southwest oncology group. *Cancer Treat Rep* 60(2):189–192
- Yamagata S, Ohmori S, Suzuki N, Yoshino M, Hino M, Ishii I, Kitada M (1998) Metabolism of dacarbazine by rat liver microsomes contribution of CYP1A enzymes to dacarbazine N-demethylation. *J Pharmacol Exp Ther* 26(4):379–382
- Abraham DJ (2003) Burger's medicinal chemistry drug discovery, vol 5, Wiley, New Jersey, pp 1–105
- Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M (2003) Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. *Mol Cancer Ther* 2(8):753–763
- Saunders PP, Schultz GA (1970) Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno)imidazole-4(5)-carboxamide in *Bacillus subtilis*. *Biochem Pharmacol* 19(3):911–919
- http://www.rxlist.com/cgi/generic2/dacarbazine_cp.htm. Accessed 26 Nov 2005)
- <http://www.drugs.com/pdr/DACARBAZINE.html>. Accessed 26 Nov 2005)
- Skibba JL, Beal DD, Ramirez G, Bryan GT (1970) N-demethylation of the antineoplastic agent 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide by rats and man. *Cancer Res* 30(1):147–150

11. Skibba JL, Bryan GT (1971) Methylation of nucleic acids and urinary excretion of 14 C-labeled 7-methylguanine by rats and man after administration of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide. *Toxicol Appl Pharmacol* 18(3):707–719
12. Mizuno NS, Humphry EW (1972) Metabolism of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in human and animal tumor tissue. *Cancer Chemother Rep* 56(4):465–472
13. Mizuno NS, Decker RW, Zakis B (1975) Effects of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347), an alkylating agent derived from 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). *Biochem Pharmacol* 24(5):615–619
14. Long L, Dolan ME (2001) Role of cytochrome P450 isoenzymes in metabolism of O (6)-benzylguanine: implications for dacarbazine activation. *Clin Cancer Res* 7(12):4239–4244
15. <http://redpoll.pharmacy.ualberta.ca/drugbank/>. Accessed 1 Jan 2006
16. Farquhar D, Benvenuto J (1984) 1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). *J Med Chem* 27(12):1723–1727
17. Catapano CV, Broggin M, Erba E, Ponti M, Mariani L, Citti L, D'Incalci M (1987) In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. *Cancer Res* 47(18):4884–4889
18. Daidone G, Maggio B, Raffa D, Plescia S, Schillaci D, Raimondi MV (2004) Synthesis and in vitro antileukemic activity of new 4-triazenopyrazole derivatives. *Farmaco* 59(5):413–417
19. Pourahmad J, O'Brien PJ (2000) A comparison of hepatocyte cytotoxic mechanisms for Cu²⁺ and Cd²⁺. *Toxicology* 143:263–273
20. Pourahmad J, O'Brien PJ, Jokar F, Daraei B (2003) Carcinogenic metal induced sites of reactive oxygen species formation in hepatocytes. *Toxico In Vitro* 17:803–810
21. Shen HM, Shic Y, Shen A, Ong CN (1996) Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1. *Free Radical Biol Med* 21:139–146
22. Pourahmad J, Ross S, O'Brien PJ (2001) Lysosomal involvement in hepatocyte cytotoxicity induced by Cu²⁺ but not Cd²⁺. *Free Rad Biol Med* 30:89–97
23. Smith MT, Thor H, Hartzell P, Orrenius S (1982) The measurement of lipid peroxidation in isolated hepatocytes. *Biochem Pharmacol* 31:19–26
24. Siraki AG, Pourahmad J, Chan TS, Khan S, O'Brien PJ (2002) Endogenous and endobiotic induced reactive oxygen species formation by isolated hepatocytes. *Free Rad Biol Med* 32:2–10
25. Hallinan T, Gor J, Rice-Evans CA, Stanley R, O'Reilly R, Brown D (1991) Lipid peroxidation in electroporated hepatocytes occurs much more readily than does hydroxyl-radical formation. *Biochem J* 277:767–771
26. Moridani MY, Scobie H, Jamshidzadeh A, Salehi P, O'Brien PJ (2001) Caffeic acid, chlorogenic acid, and dihydrocaffeic acid metabolism: glutathione conjugate formation. *Drug Metab Dispos* 29(11):1432–1439
27. Khan S, Sood C, O'Brien PJ (1993) Molecular mechanisms of dibromoalkane cytotoxicity in isolated rat hepatocytes. *Biochem Pharmacol* 45(2):439–447
28. Graham RM, Morgan EH, Baker E (1998) Characterisation of citrate and iron citrate uptake by cultured rat hepatocytes. *J Hepatol* 29:603–613
29. Luiken JJ, Aerts JM, Meijer AJ (1996) The role of the intralysosomal pH in the control of autophagic proteolytic flux in rat hepatocytes. *Eur J Biochem* 235:564–573
30. Brunk UT, Zhang H, Dalen H, Ollinger K (1995) Exposure of cells to nonlethal concentrations of hydrogen peroxide induces degeneration-repair mechanisms involving lysosomal destabilization. *Free Rad Biol Med* 19:813–822
31. Seglen PO (1997) DNA ploidy and autophagic protein degradation as determinants of hepatocellular growth and survival. *Cell Biol Toxicol* 13:301–315
32. Pourahmad J, Khan S, O'Brien PJ (2001) Lysosomal oxidative stress cytotoxicity induced by nitrofurantoin redox cycling in hepatocytes. *Adv Exp Med Biol* 500:261–265
33. Pourahmad J, O'Brien PJ (2001) Biological reactive intermediates that mediate chromium (VI) toxicity. *Adv Exp Med Biol* 500:203–207
34. Pourahmad J, Ross S, O'Brien PJ (2001) Lysosomal involvement in hepatocyte cytotoxicity induced by Cu⁽²⁺⁾ but not Cd⁽²⁺⁾. *Free Radic Biol Med* 30(1):89–97
35. Kuhn SH, Gemperli MB, De Beer FC (1985) Effect of two gold compounds on human polymorphonuclear leukocyte lysosomal function and phagocytosis. *Inflammation* 9:39–44
36. Olbricht CJ, Fink M, Guljahr E (1991) Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity. *Kidney Int* 39:639–646